Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

UroGen Pharma, Ltd.

https://www.urogen.com/

Latest From UroGen Pharma, Ltd.

Biotechs Face Daunting Launch Environment Going It Alone

Several small biotechs are launching new drugs independently in a launch environment that now presents unexpected challenges caused by COVID-19.

Sales & Earnings Launches

US FDA’s Oncology Center In The Lockdown: ‘Business As Usual’

Amid the COVID-19 pandemic, Richard Pazdur doesn’t want the cancer patient forgotten. His solution: keep churning out approvals.

Cancer Approvals

Keeping Track: US FDA Clears Oncologics Tukysa And Jelmyto; Regeneron Anti-Ebola Cocktail Under Review

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

UroGen Wins First FDA Approval With Jelmyto For Urothelial Cancer

Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology. 

Launches Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Medical Devices
    • Biomaterials
UsernamePublicRestriction

Register